叶酸-壳聚糖载地西他滨纳米粒的制备及对舌癌细胞的靶向抑制作用

›› 2017, Vol. 37 ›› Issue (11): 997-1001.

叶酸-壳聚糖载地西他滨纳米粒的制备及对舌癌细胞的靶向抑制作用

彭欢¹,黄旋平²,刘雪莹¹,林曦²,徐华生¹

1. 广西医科大学
2. 广西医科大学附属口腔医院

收稿日期:2017-04-12 修回日期:2017-05-12 出版日期:2017-11-28 发布日期:2017-11-24
通讯作者: 黄旋平 E-mail:hxp120@126.com
基金资助:
广西高校科学技术研究项目;广西壮族自治区科技计划项目;广西医疗卫生适宜技术开发与推广应用项目

Preparation of folate-chitosan loaded decitabine nanoparticles and targeting inhibition effect on tongue carcinoma cells

Received:2017-04-12 Revised:2017-05-12 Online:2017-11-28 Published:2017-11-24

摘要/Abstract

摘要： 目的：合成性质稳定的叶酸壳聚糖纳米粒，并加载地西他滨，观察其对舌癌SCC-9细胞的抑制率。方法：我们采用离子交联法合成叶酸壳聚糖载地西他滨纳米粒，测其形态、平均粒径、电位，检测载药率以及包封率，并观察纳米粒作用于舌癌细胞后，载药纳米粒对舌癌细胞的抑制作用。结果：叶酸壳聚糖载药纳米粒平均粒径为212 nm，Zeta电位为31.8 mV,性质稳定。载药纳米粒的包封率为75%，载药率为18%。载药纳米粒组较单纯加药组对舌癌细胞SCC-9抑制率高。结论：叶酸壳聚糖载DAC纳米粒成功合成，性质稳定，载药率以及包封率较高，能够靶向作用于舌癌细胞SCC-9,抑制SCC-9的生长。

关键词: 叶酸 , 壳聚糖, 地西他滨, 舌癌

Abstract: Objective　To prepare stable DAC loaded folate-chitosan nanoparticles and explore the inhibition effect on SCC-9.Methods　DAC loaded folate-chitosan nanoparticles were prepared by ionically cross-linking method. The physicochemical properties of the obtained NPs were characterized by dynamic light-scattering analysis for their mean size, size distribution, loading ratio, encapsulation efficiency and zeta potential; transmission electron microscopy for surface morphology; the nanoparticles were targeted to detect their effect on cells of tongue tumor SCC-9.Results　The average particle size of The nanoparticles was 212 nm. Zeta potential was 31.8mv.The drug encapsulation efficiency(EE) was 75%，and loading capacity(LC) was 18%. The DAC/FA-CS-NPs exhibited better than DAC alone. Conclusion　The DAC loaded FA–CS nanoparticles are stable, loading ratio and encapsulation efficiency are higher and can target at and inhibit SCC-9.

Key words: folate, chitosan, decitabine, tongue cancer

中图分类号:

R739.85

彭欢黄旋平刘雪莹林曦徐华生. 叶酸-壳聚糖载地西他滨纳米粒的制备及对舌癌细胞的靶向抑制作用[J]. , 2017, 37(11): 997-1001.

参考文献

[1]Shentu J,Wu J,Song W,et al.Chitosan microspheres as immobilized dye affinity support for catalase adsorption[J].Int J BiolMacromol,2005,37(1-2):42-46
[2]Li P,Wang Y,Zeng F,et al.Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells[J].Carbohydr Res,2011,346(6):801-806
[3]Assaraf YG,Leamon CP,Reddy JA.The folate receptor as a rational therapeutic target for personalized cancer treatment[J].Drug Resist Updat,2014,17(4-6):89-95
[4]Li TS,Yawata T,Honke K.Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy[J].Eur J Pharm Sci,2014,52:48-61
[5]Pliml J,?orm F.Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine[J].Coll Czech ChemCommun,1964,29(10):2576-2578
[6]Sorm F,Vesely J.Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic t4s in AKR mice[J].Neoplasma,1968,15(4):339-343
[7]Appleton K,Mackay HJ,Judson I,et al.Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors[J].J ClinOncol,2007,25(29):4603-4609
[8]Glasspool RM,Brown R,Gore ME,et al.A randomised,phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent,partially platinum-sensitive ovarian cancer[J].Br J Cancer,2014,110(8):1923-1929
[9]Li X,Mei Q,Nie J,et al.Decitabine: a promising epi-immunotherapeutic agent in solid tumors[J].Expert Rev ClinImmunol,2015,11(3):363-375
[10]Gnyszka A,Jastrzebski Z,Flis S.DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer[J].Anticancer Res,2013,33(8):2989-2996
[11]Bugnicourt L,Ladavière C.Interests of chitosan nanoparticles ionically cross-linked with tripolyphosphate for biomedical applications[J].Progress in Polymer Science,2016,60:1-17
[12]Jain A,Thakur K,Sharma G,et al.Fabrication,characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles[J].CarbohydrPolym,2016,137:65-74
[13]Prabaharan M.Chitosan-based nanoparticles for tumor-targeted drug delivery[J].Int J BiolMacromol,2015,72:1313-1322
[14]徐华生,黄旋平,林曦.地西他滨对人鳞状上皮舌癌SCC-9细胞p16基因甲基化状态及mRNA和蛋白表达的影响与意义[J].实用医学杂志,2016,32(16):2613-2616
[15]Lai C,Yu X,Zhuo H,et al.Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma[J].J Biomed Nanotechnol,2014,10(12):3576-3589
[16]Gaspar V M,Costa E C,Queiroz J A,et al.Folate-targeted multifunctional amino acid-chitosan nanoparticles for improved cancer therapy[J].Pharmaceutical Research,2015,32(2):562-577
[17]Dhas N L,Ige P P,Kudarha R R.Design,optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer[J].Powder Technology,2015,283:234-245
[18]Polyák A,Hajdu I,Bodnár M,et al.Folate receptor targeted self-assembled chitosan-based nanoparticles for SPECT/CT imaging: demonstrating a preclinical proof of concept[J].Int J Pharm,2014,474(1-2):91-94
[19]Wang F,Yang S,Hua D,et al.A novel preparation method of paclitaxcel-loaded folate-modified chitosan microparticles and in vitro evaluation[J].J BiomaterSciPolym Ed,2016,27(3):276-289
[20]Xu S,Xu Q,Zhou J,et al.Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery[J].J NanosciNanotechnol,2013,13(1):129-138